Keros Therapeutics Inc
KROS
查看详细走势图
10.730USD
-0.350-3.16%
交易中 （美东）报价延迟15分钟
205.91M总市值
4.59市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.16%
5天
-2.09%
1月
-24.38%
6月
-32.72%
今年开始到现在
-47.30%
1年
-0.55%
查看详细走势图
TradingKey Keros Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Keros Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力稳定。当前估值合理，在生物技术与医疗研究行业排名51/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价23.29。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Keros Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Keros Therapeutics Inc亮点
亮点风险
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
业绩高增长
公司营业收入稳步增长，连续3年增长161529.80%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值4.54，处于3年历史高位
机构减仓
最新机构持股29.78M股，环比减少50.32%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值1.96K
分析师目标
根据
9
位分析师
买入
评级
23.286
目标均价
+110.16%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Keros Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Keros Therapeutics Inc简介
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
公司代码KROS
公司Keros Therapeutics Inc
CEOSeehra (Jasbir)
网址https://www.kerostx.com/
相关品种
